December 19, 2014 / 8:17 am, CET

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY) was informed today that its partner Roche (SIX: RO, ROG; OTCQX: RHHBY) has decided to discontinue the phase 3 SCarletRoAD trial of gantenerumab in prodromal Alzheimer's Disease patients. The decision is based on a pre-planned futility analysis and a recommendation by the independent Data Monitoring Committee. According to Roche, no new safety signals were observed in the SCarletRoAD trial and the overall safety profile was similar to that seen in the phase 1 study. The second Roche-sponsored phase 3 trial of gantenerumab in mild Alzheimer's Disease patients (Marguerite RoAD) will continue. Today's news has no impact on MorphoSys's financial guidance.

END OF AD HOC ANNOUNCEMENT

About MorphoSys:

MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 90 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com.

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia® and 100 billion high potentials® are registered trademarks of MorphoSys AG.

Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a subsidiary of MorphoSys AG.

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.

For more information, please contact:

MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR

Mario Brkulj
Associate Director Corporate Communications & IR

Alexandra Goller
Specialist Corporate Communications & IR

Jessica Rush
Specialist Corporate Communications & IR

Tel: +49 (0) 89 / 899 27-404
investors@morphosys.com

distributed by